Clinical Trial Update: GM-CSF, Sargramostim in Women With Recurrent Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial results for GM-CSF (sargramostim) in women with recurrent ovarian cancer (including fallopian tube cancer) have been completed and result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer

Drugs mentioned

• Leukine (sargramostim)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Status: COMPLETED | Results posted: 2017-05-08